Superior HbA1c control with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double‐blind, randomized trial - Watada, Hirotaka; Kaneko, Shizuka; Komatsu, Mitsuhisa; Agner, Bue Ross; Nishida, Tomoyuki; Ranthe, Mattis; Nakamura, Jiro (Diabetes, obesity & metabolism, 2019)
Keywords: Aged; basal insulin; Blood Glucose - analysis; Diabetes Mellitus, Type 2 - drug therapy; Double-Blind Method; Female; Glycated Hemoglobin A - analysis; Humans; hypoglycaemia; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Insulin, Long-Acting - administration & dosage; Insulin, Long-Acting - adverse effects; Insulin, Long-Acting - therapeutic use; Japan; liraglutide; Liraglutide - administration & dosage; Liraglutide - adverse effects; Liraglutide - therapeutic use; Male; Middle Aged; Original; randomized trial; type 2 diabetes; Japan; liraglutide; basal insulin; type 2 diabetes; hypoglycaemia; randomized trial